Search

Your search keyword '"Pomper, Martin G"' showing total 2,114 results
Start Over Author "Pomper, Martin G"
2,114 results on '"Pomper, Martin G"'

4. [18F]FNDP PET neuroimaging test–retest repeatability and whole-body dosimetry in humans

Author

Du, Yong, Coughlin, Jennifer M., Amindarolzarbi, Alireza, Sweeney, Shannon Eileen, Harrington, Courtney K., Brosnan, Mary Katherine, Zandi, Adeline, Shinehouse, Laura K., Sanchez, Alejandra N. Reyes, Abdallah, Rehab, Holt, Daniel P., Fan, Hong, Lesniak, Wojciech G., Nandi, Ayon, Rowe, Steven P., Solnes, Lilja B., Dannals, Robert F., Horti, Andrew G., Lodge, Martin A., and Pomper, Martin G.

Published
2023
Full Text
View/download PDF

8. Small Molecules as Vectors for Radiopharmaceutical Therapy

Author

Rowe, Steven P., Werner, Rudolf A., Garg, Tushar, Gafita, Andrei, Voter, Andrew F., Sadaghiani, Mohammad S., Markowski, Mark C., Paller, Channing J., Zalutsky, Micheal R., Solnes, Lilja B., Pomper, Martin G., Bodei, Lisa, editor, Lewis, Jason S., editor, and Zeglis, Brian M., editor

Published
2023
Full Text
View/download PDF

14. A Physics-Guided Modular Deep-Learning Based Automated Framework for Tumor Segmentation in PET Images

Author

Leung, Kevin H., Marashdeh, Wael, Wray, Rick, Ashrafinia, Saeed, Pomper, Martin G., Rahmim, Arman, and Jha, Abhinav K.

Subjects
Physics - Medical Physics, Electrical Engineering and Systems Science - Image and Video Processing
Abstract

The objective of this study was to develop a PET tumor-segmentation framework that addresses the challenges of limited spatial resolution, high image noise, and lack of clinical training data with ground-truth tumor boundaries in PET imaging. We propose a three-module PET-segmentation framework in the context of segmenting primary tumors in 3D FDG-PET images of patients with lung cancer on a per-slice basis. The first module generates PET images containing highly realistic tumors with known ground-truth using a new stochastic and physics-based approach, addressing lack of training data. The second module trains a modified U-net using these images, helping it learn the tumor-segmentation task. The third module fine-tunes this network using a small-sized clinical dataset with radiologist-defined delineations as surrogate ground-truth, helping the framework learn features potentially missed in simulated tumors. The framework's accuracy, generalizability to different scanners, sensitivity to partial volume effects (PVEs) and efficacy in reducing the number of training images were quantitatively evaluated using Dice similarity coefficient (DSC) and several other metrics. The framework yielded reliable performance in both simulated (DSC: 0.87 (95% CI: 0.86, 0.88)) and patient images (DSC: 0.73 (95% CI: 0.71, 0.76)), outperformed several widely used semi-automated approaches, accurately segmented relatively small tumors (smallest segmented cross-section was 1.83 cm2), generalized across five PET scanners (DSC: 0.74), was relatively unaffected by PVEs, and required low training data (training with data from even 30 patients yielded DSC of 0.70). In conclusion, the proposed framework demonstrated the ability for reliable automated tumor delineation in FDG-PET images of patients with lung cancer.

Published
2020
Full Text
View/download PDF

18. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Author

Miyahira, Andrea K, Pienta, Kenneth J, Babich, John W, Bander, Neil H, Calais, Jeremie, Choyke, Peter, Hofman, Michael S, Larson, Steven M, Lin, Frank I, Morris, Michael J, Pomper, Martin G, Sandhu, Shahneen, Scher, Howard I, Tagawa, Scott T, Williams, Scott, and Soule, Howard R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Prostate Cancer, Aging, Cancer, Biomedical Imaging, Good Health and Well Being, Humans, Male, Molecular Targeted Therapy, Precision Medicine, Prostatic Neoplasms, Theranostic Nanomedicine, clinical trials, medical oncology, nuclear medicine, PET imaging, prostate-specific membrane antigen, radiation therapy, radiology, radionuclides, radiopharmaceuticals, urology, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionThe Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY.MethodsThe meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer.ResultsSeveral major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT.DiscussionThis article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.

Published
2020

24. High-potency ligands for DREADD imaging and activation in rodents and monkeys.

Author

Bonaventura, Jordi, Eldridge, Mark AG, Hu, Feng, Gomez, Juan L, Sanchez-Soto, Marta, Abramyan, Ara M, Lam, Sherry, Boehm, Matthew A, Ruiz, Christina, Farrell, Mitchell R, Moreno, Andrea, Galal Faress, Islam Mustafa, Andersen, Niels, Lin, John Y, Moaddel, Ruin, Morris, Patrick J, Shi, Lei, Sibley, David R, Mahler, Stephen V, Nabavi, Sadegh, Pomper, Martin G, Bonci, Antonello, Horti, Andrew G, Richmond, Barry J, and Michaelides, Michael

Subjects
Brain, Animals, Haplorhini, Humans, Rodentia, Fluorine Radioisotopes, Clozapine, Designer Drugs, Ligands, Positron-Emission Tomography, Neuronal Tract-Tracers, Neuroanatomical Tract-Tracing Techniques, HEK293 Cells, Biomedical Imaging, Neurosciences
Abstract

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for human applications as well. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and converts to clozapine, making it difficult to apply in basic and translational applications. Here we report the development of two novel DREADD agonists, JHU37152 and JHU37160, and the first dedicated 18F positron emission tomography (PET) DREADD radiotracer, [18F]JHU37107. We show that JHU37152 and JHU37160 exhibit high in vivo DREADD potency. [18F]JHU37107 combined with PET allows for DREADD detection in locally-targeted neurons, and at their long-range projections, enabling noninvasive and longitudinal neuronal projection mapping.

Published
2019

31. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.

Author

Murthy, Vishnu, Voter, Andrew F., Nguyen, Kathleen, Allen-Auerbach, Martin, Chen, Lucia, Caputo, Sydney, Ledet, Elisa, Akerele, Abraham, Moradi Tuchayi, Abuzar, Lawhn-Heath, Courtney, Wang, Tingchang, Carducci, Michael A., Pomper, Martin G., Paller, Channing J., Czernin, Johannes, Solnes, Lilja B., Hope, Thomas A., Sartor, Oliver, Calais, Jeremie, and Gafita, Andrei

Published
2024
Full Text
View/download PDF

32. Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.

Author

Gafita, Andrei, Voter, Andrew, Shesadri, Somya, Spitz, Avery, Marshall, Catherine H., Rowe, Steven P., Markowski, Mark C., Pomper, Martin G., Civelek, A. Cahid, Carducci, Michael A., Denmeade, Samuel R., Young, Jeffrey, Pienta, Kenneth J., Paller, Channing J., and Solnes, Lilja B.

Published
2024
Full Text
View/download PDF

33. Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.

Author

Singh, Rajan, Thotakura, Anand K., Alati, Suresh, Lisok, Alla, Zirui Jiang, Merino, Vanessa F., Minn, Il, Yadav, Santosh, Markowski, Mark C., Ged, Yasser, Pavlovich, Christian P., Singla, Nirmish, Solnes, Lilja B., Gorin, Michael A., Pomper, Martin G., Rowe, Steven P., and Banerjee, Sangeeta Ray

Subjects
PROSTATE-specific membrane antigen, MAGNETIC resonance imaging, RADIOCHEMICAL purification, COMPUTED tomography, RENAL cancer, RENAL cell carcinoma
Abstract

Introduction: Renal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostatespecific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular endothelial cells of many solid tumors, including metastatic RCC. Although studied in several small clinical studies, PSMA-based imaging and therapy have not been pursued rigorously in preclinical RCC. This study aimed to evaluate the preclinical performance of PSMA-based radiotheranostic agents in a relevant murine model. Methods: A PSMA-overexpressing murine cell line, PSMA+ RENCA, was developed by lentiviral transduction. PSMA-based theranostic agents, 68Ga-L1/177Lu-L1/225Ac-L1, were synthesized in high radiochemical yield and purity following our reported methods. Immunocompetent BALB/c mice were used for flank and orthotopic tumor inoculation. 68Ga-L1 was evaluated in small animal PET/CT imaging in flank and PET/MR imaging in orthotopic models. Cell viability studies were conducted for 177Lu-L1 and 225Ac-L1. Proof-of-concept treatment studies were performed using 225Ac-L1 (0, 37 kBq, 2 kBq × 37 kBq, 1 week apart) using PSMA+ RENCA in the flank model. Results: Cellular uptake of 68Ga-L1, 177Lu-L1, and 225Ac-L1 confirmed the specificity of the agents to PSMA+ RENCA cells rather than to RENCA (wt) cells, which are low in PSMA expression. The uptake in PSMA+ RENCA cells at 1 h for 68Ga-L1 (49.0% incubated dose [ID] ± 3.6%ID/million cells), 177Lu-L1 (22.1% ID ± 0.5%ID)/million cells), and 225Ac-L1 (4.1% ± 0.2% ID)/million cells), respectively, were higher than the RENCA (wt) cells (~ 1%ID-2%ID/million cells). PET/CT images displayed > 7-fold higher accumulation of 68Ga-L1 in PSMA+ RENCA compared to RENCA (wt) in flank implantation at 1 h. A twofold higher accumulation of 68Ga-L1 was observed in orthotopic tumors than in normal kidneys during 1-3 h postinjection. High lung uptake was observed with 68Ga-L1 PET/MR imaging 3 weeks after orthotopic implantation of PSMA+ RENCA due to spontaneous lung metastases. The imaging data were further confirmed by immunohistochemical characterization. 225Ac-L1 (0-37 kBq) displayed a dose-dependent reduction of cell proliferation in the PSMA+ RENCA cells after 48 h incubation; ~ 40% reduction in the cells with treated 37 kBq compared to vehicle (p < 0.001); however, no effect was observed with 177Lu-L1 (0-3700 kBq) up to 144 h postinoculation, suggesting lower efficacy of β-particle-emitting radiations in cellular studies compared to a-particle-emitting 225Ac-L1. Animals treated with 225Ac-L1 at 1 week posttumor inoculation in flank models displayed significant tumor growth delay (p < 0.03) and longer median survival of 21 days and 24 days for the treatment groups 37 kBq and 2 kBq × 37 kBq, respectively, compared to the vehicle group (12 days). Conclusion: The results suggest that a theranostic strategy targeting PSMA, employing PET and α-emitting radiopharmaceuticals, enabled tumor growth control and enhanced survival in a relevant immunocompetent murine model of RCC. These studies provide the rationale for clinical studies of PSMA-targeted theranostic agents in patients with RCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy

Author

Lu, Dai-Yin, Yalçin, Hulya, Yalçin, Fatih, Zhao, Min, Sivalokanathan, Sanjay, Valenta, Ines, Tahari, Abdel, Pomper, Martin G, Abraham, Theodore P, Schindler, Thomas H, and Abraham, M Roselle

Subjects
Cardiovascular, Clinical Research, Biomedical Imaging, Heart Disease, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Academic Medical Centers, Adult, Aged, Baltimore, Biomarkers, Cardiomyopathy, Hypertrophic, Cohort Studies, Death, Sudden, Cardiac, Disease Progression, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Perfusion Imaging, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prognosis, Proportional Hazards Models, ROC Curve, Registries, Retrospective Studies, Risk Assessment, Stroke Volume, Survival Analysis, Tachycardia, Ventricular, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

Patients with hypertrophic cardiomyopathy (HC) are at increased risk of sudden cardiac death. Abnormalities in myocardial blood flow (MBF) detected by positron emission tomography (PET) are common in HC, but a PET marker that identifies patients at risk of sudden cardiac death is lacking. We hypothesized that disparities in regional myocardial perfusion detected by PET would identify patients with HC at risk of ventricular arrhythmias. To test this hypothesis, we quantified global and regional MBFs by 13NH3-PET at rest and at stress, and developed a heterogeneity index to assess MBF heterogeneity in 133 symptomatic patients with HC. The MBF heterogeneity index was computed by dividing the highest by the lowest regional MBF value, at rest and after vasodilator stress, in each patient. High stress MBF heterogeneity was defined as an index of ≧1.85. Patients with HC were stratified by the presence or the absence of ventricular arrhythmias, defined as sustained ventricular tachycardia (VT) and/or nonsustained VT, during follow-up. We found that global and regional MBFs at rest and stress were similar in patients with HC with or without ventricular arrhythmias. Variability in regional stress MBF was observed in both groups, but the stress MBF heterogeneity index was significantly higher in patients with HC who developed ventricular arrhythmias (1.82 ± 0.77 vs 1.49 ± 0.25, p

Published
2018

37. 491. Higher Availability of the α7 Nicotinic Acetylcholine Receptor in the Brains of Older, Cognitively Normal Individuals

Author

Woolsey, Alejandra, primary, Jenkins, Katelyn R., additional, Harrington, Courtney K., additional, Miller, Hannah M., additional, Soule, Ana R., additional, Du, Yong, additional, Horti, Andrew G., additional, Pomper, Martin G., additional, Bakker, Arnold, additional, Rubin, Leah H., additional, and Coughlin, Jennifer M., additional

Published
2024
Full Text
View/download PDF

39. Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T

Author

Hartrampf, Philipp E., primary, Hüttmann, Thomas, additional, Seitz, Anna Katharina, additional, Kübler, Hubert, additional, Serfling, Sebastian E., additional, Higuchi, Takahiro, additional, Schlötelburg, Wiebke, additional, Michalski, Kerstin, additional, Gafita, Andrei, additional, Rowe, Steven P., additional, Pomper, Martin G., additional, Buck, Andreas K., additional, and Werner, Rudolf A., additional

Published
2024
Full Text
View/download PDF

40. CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer

Author

Yan, Yu, Narayan, Athira, Cho, Soonweng, Cheng, Zhiqiang, Liu, Jun O., Zhu, Heng, Wang, Guannan, Wharram, Bryan, Lisok, Ala, Brummet, Mary, Saeki, Harumi, Huang, Tao, Gabrielson, Kathleen, Gabrielson, Edward, Cope, Leslie, Kanaan, Yasmine M., Afsari, Ali, Naab, Tammey, Yfantis, Harris G., Ambs, Stefan, Pomper, Martin G., Sukumar, Saraswati, and Merino, Vanessa F.

Published
2021
Full Text
View/download PDF

44. Future cancer research priorities in the USA: a Lancet Oncology Commission

Author

Jaffee, Elizabeth M, Van Dang, Chi, Agus, David B, Alexander, Brian M, Anderson, Kenneth C, Ashworth, Alan, Barker, Anna D, Bastani, Roshan, Bhatia, Sangeeta, Bluestone, Jeffrey A, Brawley, Otis, Butte, Atul J, Coit, Daniel G, Davidson, Nancy E, Davis, Mark, DePinho, Ronald A, Diasio, Robert B, Draetta, Giulio, Frazier, A Lindsay, Futreal, Andrew, Gambhir, Sam S, Ganz, Patricia A, Garraway, Levi, Gerson, Stanton, Gupta, Sumit, Heath, James, Hoffman, Ruth I, Hudis, Cliff, Hughes-Halbert, Chanita, Ibrahim, Ramy, Jadvar, Hossein, Kavanagh, Brian, Kittles, Rick, Le, Quynh-Thu, Lippman, Scott M, Mankoff, David, Mardis, Elaine R, Mayer, Deborah K, McMasters, Kelly, Meropol, Neal J, Mitchell, Beverly, Naredi, Peter, Ornish, Dean, Pawlik, Timothy M, Peppercorn, Jeffrey, Pomper, Martin G, Raghavan, Derek, Ritchie, Christine, Schwarz, Sally W, Sullivan, Richard, Wahl, Richard, Wolchok, Jedd D, Wong, Sandra L, and Yung, Alfred

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Cancer, Rare Diseases, Clinical Research, Good Health and Well Being, Biomedical Research, Forecasting, Health Planning, Health Priorities, Humans, Medical Oncology, National Cancer Institute (U.S.), Neoplasms, Precision Medicine, United States, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

Published
2017

45. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia

Author

Coughlin, Jennifer M., Yang, Kun, Marsman, Anouk, Pradhan, Subechhya, Wang, Min, Ward, Rebecca E., Bonekamp, Susanne, Ambinder, Emily B., Higgs, Cecilia P., Kim, Pearl K., Edwards, Jamie A., Varvaris, Mark, Wang, Hongxing, Posporelis, Sotirios, Ma, Shuangchao, Tsujimura, Tsuyoshi, Edden, Richard A. E., Pomper, Martin G., Sedlak, Thomas W., Fournier, Margot, Schretlen, David J., Cascella, Nicola G., Barker, Peter B., and Sawa, Akira

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results